Anagenics (ASX:AN1) said it expects to complete the relisting of its securities on the Australian Securities Exchange by the end of February, following the submission of additional required information to the exchange, according to a Jan. 10 filing with the Australian bourse.

The additional information required includes its quarterly activities report, an audit-reviewed financial statement, and confirmation of sufficient operations and financial standing following its recent restructure, the filing said.